Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 3910 Reports

🤖 AI Analyzed

Recent

📄 Page 212 of 326

PEOPLES FINANCIAL CORP /MS/

10-K March 18, 2026

Key Highlights

Strong financial performance: 8% net income growth to $15.2 million and 6% total...
Robust financial health: Total assets grew 5% to $1.2 billion, with low non-perf...
Strategic capital allocation: Completed a $7.1 million share repurchase program ...

Read Analysis

🤖 AI Generated

XOMA Royalty Corp

10-K March 18, 2026

Key Highlights

Achieved robust financial growth in 2023 with 25% revenue increase to $55.0 mill...
Strategically expanded a diversified portfolio of commercial and clinical-stage ...
Secured a significant $100 million BlueOwl term loan, providing substantial capi...

Read Analysis

🤖 AI Generated

TAT TECHNOLOGIES LTD

20-F March 18, 2026

Key Highlights

Achieved robust financial growth in 2025 with 15% revenue increase to $125 milli...
Maintains a strong financial health with $35 million cash and a low debt-to-equi...
Specializes in critical heat transfer solutions and essential aviation component...

Read Analysis

🤖 AI Generated

Neonode Inc.

10-K March 18, 2026

Key Highlights

Proprietary zForce® optical touch and gesture technology offers unique non-conta...
Focus on high-growth verticals like medical, industrial, and automotive where it...
Strong gross margin of approximately 65% on its technology and product sales.

Read Analysis

🤖 AI Generated

CENTURY CASINOS INC /CO/

10-K March 18, 2026

Key Highlights

Achieved significant financial turnaround with $550 million revenue (15% increas...
Adjusted EBITDA grew 22% to $120 million, indicating strong operational profitab...
Successfully integrated the newly acquired Rocky Gap Casino Resort, significantl...

Read Analysis

🤖 AI Generated

MGT CAPITAL INVESTMENTS, INC.

10-K March 17, 2026

Key Highlights

MGT Capital is actively seeking a new strategic direction and business opportuni...
The company has successfully brought its SEC filings up to date, ensuring transp...
Management is intensely focused on capital preservation and maintaining a lean o...

Read Analysis

🤖 AI Generated

ELBIT SYSTEMS LTD

20-F March 17, 2026

Key Highlights

Achieved strong financial results in 2023 with approximately $6.0 billion in rev...
Secured a record backlog of $17.8 billion by year-end 2023, providing clear visi...
Maintains a global leadership position in defense and security technologies with...

Read Analysis

🤖 AI Generated

Eloxx Pharmaceuticals, Inc.

10-K March 17, 2026

Key Highlights

Lead candidate ELX-02 is in Phase Two clinical development for Cystic Fibrosis, ...
Secured a strategic licensing agreement with Almirall in March 2024, potentially...
Focused on discovering and developing novel RNA-modulating medicines for rare di...

Read Analysis

🤖 AI Generated

CAMPBELL FUND TRUST

10-K March 17, 2026

Key Highlights

Operates as an investment fund focused on growing investors' capital through str...
Employs a broad and diversified investment approach across various asset classes...
Actively uses complex derivatives for hedging, income generation, and potential ...

Read Analysis

🤖 AI Generated

AXT INC

10-K March 17, 2026

Key Highlights

Planned IPO of majority-owned Chinese subsidiary, Tongmei, on Shanghai's STAR Ma...
Leading manufacturer of high-performance compound semiconductor substrates (GaAs...
Strategic divestment of 15% of Jia Mei investment, optimizing portfolio manageme...

Read Analysis

🤖 AI Generated

XEROX CORP

10-K March 17, 2026

Key Highlights

Xerox is actively pivoting towards IT solutions and services through strategic a...
Management is executing a "Reinvention" strategy to stabilize core print and acc...
Despite net losses, the company generated $300 million in cash from operating ac...

Read Analysis

🤖 AI Generated

CAPRICOR THERAPEUTICS, INC.

10-K March 17, 2026

Key Highlights

Completed patient enrollment for its pivotal Phase 3 clinical trial (HOPE-3) of ...
Expects to report initial (top-line) data from the Phase 3 HOPE-3 trial in the t...
Secured Fast Track designation from the FDA for another pipeline candidate, acce...

Read Analysis

🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage